Maiz Cristóbal, Silva Fernando, Domínguez Francisco, Galindo Héctor, Camus Mauricio, León Augusto, Oddó David, Villarroel Alejandra, Razmilic Dravna, Navarro María Elena, Medina Lidia, Merino Tomás, Vines Eugenio, Peña José, Maldonado Daniela, Pinto Mauricio P, Acevedo Francisco, Sánchez César
Departament of Oncological and Maxillofacial Surgery, School of Medicine, Pontificia Universidad Católica de Chile, 8330032 Santiago, Chile.
Departament of Hematology and Oncology, School of Medicine, Pontificia Universidad Católica de Chile, 8330032 Santiago, Chile.
Ecancermedicalscience. 2020 Jan 23;14:1005. doi: 10.3332/ecancer.2020.1005. eCollection 2020.
Breast cancer (BC) is the most common malignancy in women. We retrieved medical records from >2,000 Chilean BC patients over the 1997-2018 period. The objective was to assess changes in clinical presentation or prognosis of our patients throughout these 20 years of practice. Although most variables did not display significant variations, we observed a progressive increase in stage IV BC over this period. Our data showed that tumour stage III/IV or HER2-enriched subtype tumours were associated with poorer prognosis. In contrast, we found that patients diagnosed by mammography had better overall survival. We speculate that better screenings and more sensitive imaging could explain the unexpected rise in stage IV cases. Our results support mammography screenings as an effective measure to reduce BC-related mortality.
乳腺癌（BC）是女性中最常见的恶性肿瘤。我们检索了1997年至2018年期间2000多名智利乳腺癌患者的病历。目的是评估在这20年的实践中我们患者的临床表现或预后变化。尽管大多数变量没有显示出显著变化，但我们观察到在此期间IV期乳腺癌有逐渐增加的趋势。我们的数据表明，肿瘤III/IV期或HER2富集亚型肿瘤与较差的预后相关。相比之下，我们发现通过乳腺钼靶检查诊断出的患者总体生存率更高。我们推测更好的筛查和更灵敏的成像可以解释IV期病例意外增加的原因。我们的结果支持乳腺钼靶筛查作为降低乳腺癌相关死亡率的有效措施。
